文献速递白血病

MRD与细胞遗传学在青少年及成人B-ALL中的整合预后价值

Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.
PubMed 文献 · Br J Haematol · 2025-12-12

该回顾性研究分析609例青少年及成人B细胞急性淋巴细胞白血病患者,评估诱导结束时(MRD1)和首次巩固后(MRD2)的MRD与细胞遗传学风险分层(标危 vs 不良风险)的整合预后价值。细胞遗传学风险单独非独立预后因素,但任一时间点MRD阳性显著预测不良风险患者较差的5年RFS和OS。异基因造血干细胞移植总体改善结局,但MRD2阳性的不良风险患者移植后复发风险仍高。多变量分析确定MRD1和MRD2为不良风险患者复发和死亡的独立预测因素。

要点

  • 细胞遗传学风险单独非独立预后因素,需结合MRD评估。
  • 不良风险患者任一时间点MRD阳性预示5年RFS和OS较差。
  • MRD2阳性的不良风险患者移植后复发风险仍高。

核心结论

  • MRD评估与细胞遗传学风险结合可改善风险分层,精准识别持续MRD阳性的不良风险患者。

研究设计与样本

  • 回顾性研究分析609例青少年及成人B-ALL患者,评估MRD1和MRD2联合细胞遗传学风险分层的预后价值。

主要发现

  • 细胞遗传学风险单独非独立预后因素。
  • 不良风险患者任一时间点MRD阳性显著预测较差的5年RFS和OS。
  • 异基因造血干细胞移植总体改善结局,但MRD2阳性的不良风险患者移植后复发风险仍高。
  • 多变量分析显示MRD1和MRD2为不良风险患者复发(RFS HR=2.048)和死亡(OS HR=1.979)的独立预测因素(均p<0.01)。

临床怎么用

  • 对青少年及成人B-ALL患者,应整合MRD(诱导结束和首次巩固后)与细胞遗传学风险进行风险分层。
  • 持续MRD阳性的不良风险患者可考虑治疗强化,包括移植后新型策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B-cell acute lymphoblastic leukaemia (B-ALL) in adolescents and adults remains challenging due to high relapse rates and suboptimal outcomes. Although minimal residual disease (MRD) and cytogenetic risk classification are independent prognostic indicators for B-ALL in adolescents and adults, their combined utility remains under explored. This retrospective study analysed 609 adolescent and adult patients with B-ALL to evaluate the integrated prognostic value of MRD at end of induction (MRD1) and after first consolidation (MRD2), combined with cytogenetic risk stratification (standard risk [SR] vs. poor risk [PR]). Although cytogenetic risk alone was not an independent prognostic factor, MRD positivity at either time point significantly predicted inferior 5-year RFS and OS in PR patients. Allogeneic haematopoietic stem cell transplantation (allo-HSCT) improved outcomes overall; however, PR patients with MRD2 positivity remained at high risk of relapse post-transplant. Multivariate analysis identified MRD1 and MRD2 as independent predictors of both relapse (RFS HR = 2.048) and mortality (OS HR = 1.979) in PR patients (all p < 0.01). These results demonstrate that combining MRD assessment with cytogenetic risk improves risk stratification, precisely identifying poor-risk patients with persistent MRD who may benefit from treatment intensification, including novel strategies post-transplant.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Gu J, Wang J, Liu L, et al. Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia. Br J Haematol. 2025. PMID: 41387940. doi:10.1111/bjh.70281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。